real peptides FAQ

Current SS-LUP-332 history includes mostly sedentary animal models—combining the compound with structured training protocols could reveal synergistic effects or ceiling effects where training alone produces maximal adaptation. One hypothesis is that SS-LUP-332 would accelerate early-phase adaptations (the first 4–6 weeks of training) but provide diminishing returns in already-trained subjects whose AMPK signaling is already upregulated. This remains an open research question as of 2026, with at least two ongoing studies examining trained vs untrained response curves.

Maintain 2–8°C temperature throughout transit using a purpose-built medication cooler with temperature logging capability. TSA regulations permit medically necessary liquids in carry-on luggage when properly labelled. Use gel-based cold packs (not loose ice) to maintain stable refrigeration without risk of freezing. Test your cooler before travel: place a calibrated thermometer inside and monitor temperature over 24 hours to confirm it stays between 2–8°C. Temperature excursions above 25°C for more than four hours reduce peptide potency by 20–30%. Once that degradation occurs, it cannot be reversed. If you cannot maintain cold chain integrity during travel, reconstitute a fresh vial at your destination rather than transporting a compromised compound.

Peptides modulate immune function. They don't replace corticosteroids or biologics for acute flare management. Autoimmune flares triggered by infection, stress, or environmental factors require immediate medical intervention, not peptide dose escalation. Peptides work over weeks to months to restore immune tolerance; they cannot abort an acute inflammatory cascade already in progress. If disease activity worsens within the first two weeks of peptide research, the timeline is too short to attribute causality to the peptide. If worsening occurs after 4–6 weeks of stable peptide use, consider whether the peptide mechanism is suppressing a compensatory pathway. For example, VIP reduces Th1 responses, which could theoretically allow Th2-mediated pathology to emerge unchecked in atopic individuals. Discontinue the peptide and revert to standard immunosuppression protocols while reassessing mechanism fit.

SS-LUP-332 preserves existing muscle during deficit but does not drive net protein accretion the way growth hormone secretagogues do. For true simultaneous fat loss and muscle gain (body recomposition in a neutral or slight surplus), consider parallel investigation of compounds targeting different pathways—CJC1295 Ipamorelin for anabolic signaling and SS-LUP-332 for substrate preference shift. Run these as separate arms initially to establish individual dose-response curves before attempting combination protocols. Attempting to achieve both endpoints with SS-LUP-332 alone will likely produce disappointing results—it's a preservation tool, not a growth promoter.

Absolutely. Lyophilized peptides must remain below 25°C during shipping, and reconstituted peptides require refrigeration at 2–8°C. Thymalin, epitalon, and GHK-Cu are all susceptible to heat denaturation. A single temperature excursion above 30°C for more than 12 hours can degrade the amino acid sequence irreversibly. If a package arrives warm or sits in a mailbox during summer, the peptide may be inactive even if it looks normal. Real Peptides ships peptides with temperature monitoring to prevent this, but verifying cold-chain integrity upon delivery is non-negotiable.

Use a washout period of at least 72 hours between compounds to minimize carryover effects. Peptides like Semax with rapid BDNF upregulation may produce measurable changes in gene expression that persist beyond plasma clearance of the compound itself. Designing parallel-group comparisons rather than crossover designs eliminates this variable entirely. For synaptogenic compounds like Dihexa or P21, structural changes (dendritic spine formation) can persist for weeks. Meaning true crossover designs are not feasible without extending study timelines significantly.

Do not use it. Lyophilized SS-LUP-332 should appear as a white to off-white powder with uniform texture—clumping, discoloration (yellow, brown, or gray tint), or crystalline chunks indicate degradation, contamination, or incorrect synthesis. Without third-party HPLC-MS verification, there is no way to confirm molecular identity or purity. Unverified suppliers frequently mislabel compounds, substitute lower-cost analogues, or provide underdosed product to reduce manufacturing costs. The risk of injecting an unknown substance or inactive powder far outweighs any potential research benefit.

Include appropriate controls and stagger administration if half-lives differ. Semax has a half-life of approximately 30 minutes in plasma but shows CNS effects lasting 24 hours due to receptor-mediated signaling. Selank's half-life is similarly short, but its anxiolytic effects persist 6–8 hours post-administration. If comparing both in the same model, match for duration of action rather than plasma half-life. Use separate control groups for each peptide to avoid carryover effects, and verify that reconstitution protocols are identical. Different solvents or pH levels can alter peptide stability and receptor affinity.

Consider encapsulation with permeation enhancers or switch to intranasal delivery. Most peptides undergo rapid enzymatic degradation in the gastrointestinal tract and have poor absorption across the intestinal epithelium due to size and charge. Dihexa is a notable exception. It was specifically designed for oral bioavailability. For other peptides, intranasal administration achieves direct CNS delivery via the olfactory epithelium and trigeminal nerve pathways, bypassing hepatic metabolism entirely. This route produces measurable hippocampal concentrations within 30 minutes and is the preferred administration method in rodent cognitive research for compounds like Semax and P21.

VIP shipping applies to the entire shipment, not individual vials. If your order contains a mix of thermally stable peptides (Glutathione, NAD 100mg) and heat-sensitive compounds (Tirzepatide, Retatrutide), the entire package ships via VIP protocol. You can't split shipping methods within one order. This is actually beneficial: even peptides marketed as "stable" perform more consistently when stored and shipped cold. Batch-to-batch variability decreases when thermal history is controlled across all compounds. The VIP shipping cost is per shipment, not per vial, so adding stable peptides to a VIP order doesn't increase shipping fees.

Prioritise BPC-157 for its direct hepatoprotective mechanism. It reduces lipid peroxidation and upregulates antioxidant enzymes that metabolise drug byproducts. Stack it with glutathione precursors (N-acetylcysteine) to maximise Phase II conjugation capacity. Monitor liver enzymes (ALT, AST) every 8–12 weeks. Peptide-mediated enzyme upregulation should correlate with normalised values if the protocol is effective.

Prioritize BPC-157 for its angiogenic effects. The Achilles insertion (enthesis) has minimal baseline vascularity, which limits immune cell recruitment, nutrient delivery, and waste removal. All critical for healing. BPC-157's upregulation of VEGF and FGF-2 promotes capillary ingrowth into the injury zone, establishing the vascular network needed to support tenocyte activity. Studies in Achilles tendon rupture models found BPC-157 administration resulted in 40% greater vascular density at 4 weeks and 25% higher ultimate tensile strength at 12 weeks compared to controls. Dosing should begin within 48–72 hours post-injury to align with the early inflammatory phase when angiogenic signaling is initiated.

MK-677's appetite-stimulating effect is driven by ghrelin receptor activation in the hypothalamus and gut. If you're eating in a surplus, the GH elevation will drive anabolism, but excess calories will still be stored as fat. The fix is either stricter caloric tracking (weighing food, tracking macros) or switching to a non-appetite-stimulating GH protocol like CJC-1295/Ipamorelin. Alternatively, stack MK-677 with Tesofensine or a GLP-1 analog to offset the appetite increase. The thermogenic and satiety effects counterbalance ghrelin-driven hunger.

The plateau is metabolic adaptation, not peptide failure. GLP-1 agonists suppress appetite and slow gastric emptying, but they don't override the body's compensatory reduction in energy expenditure that occurs with sustained weight loss. After 10-15% body weight reduction, basal metabolic rate drops 10-15% below predicted values—a phenomenon called adaptive thermogenesis. The peptide is still working at the receptor level, but total daily energy expenditure has decreased to match the reduced caloric intake. Breaking the plateau requires either increasing the peptide dose (if not yet at maximum therapeutic dose) or introducing a compound that increases energy expenditure—such as a dual GLP-1/glucagon agonist like survodutide or mazdutide, where the glucagon component raises hepatic fat oxidation and thermogenesis. Adding resistance training to increase lean mass also raises BMR independent of peptide mechanism, though the effect is gradual (2-3 months to see measurable metabolic impact).

Prioritize neuropeptides with documented BBB penetration and BDNF-modulating activity—Cerebrolysin or Semax are first-line candidates. Cerebrolysin protocols in TBI and stroke research use 10–30mL intravenous over 10–20 sessions; Semax uses 300–600mcg intranasal or subcutaneous daily. Both compounds reduce microglial activation while promoting synaptic plasticity and neurogenesis. Cognitive testing (MoCA, Trail Making Test) should be performed at baseline and 4–6 weeks to assess processing speed and executive function improvements. Unlike psychostimulants, these compounds address the underlying neuroinflammatory process rather than masking it.

The mechanism explains why pharmaceutical anti-inflammatories often fail in chronic states: NSAIDs inhibit COX-2 enzyme activity, reducing prostaglandin production and suppressing symptoms, but they do not address the upstream immune dysregulation driving cytokine release. Corticosteroids suppress NF-κB broadly but create dependency—stopping them often triggers rebound inflammation worse than the original state. Peptides modulate rather than suppress: BPC-157 normalizes angiogenesis and nitric oxide signaling without blocking prostaglandin synthesis; Thymosin Alpha-1 restores T-cell function without inducing immune paralysis. Start with the peptide that targets your dominant pathway—NF-κB for cytokine-driven inflammation (KPV), fibrosis for tissue remodeling (TB-500), immune exhaustion for infection or autoimmune states (Thymosin Alpha-1).

Compare reconstitution protocols. Peptide activity depends on proper solvent pH, ionic strength, and reconstitution sequence. Lyophilized peptides containing acidic residues (Asp, Glu) may require pH adjustment to 7.4 after reconstitution with water. Verify storage temperature history. Temperature excursions during shipping or storage cause irreversible structural changes that HPLC purity cannot detect. Examine animal model differences: C57BL/6 mice, BALB/c mice, and Sprague-Dawley rats show different baseline inflammatory responses and peptide pharmacokinetics. Finally, check for endotoxin contamination in peptide stock. Even 0.5 EU/mg endotoxin can activate TLR4 signaling and confound anti-inflammatory peptide effects.

Yes. Mechanistically they target different pathways. NAD+ boosters (NMN, NR) address mitochondrial NAD+ depletion and sirtuin activation. Senolytics (quercetin + dasatinib, fisetin) eliminate senescent cells that secrete inflammatory signals. Thymalin and epitalon work through immune modulation and telomere maintenance, neither of which overlaps with NAD+ or senolytic mechanisms. The risk is polypharmacy complexity, not pathway interference. Tracking which intervention is responsible for which benefit becomes difficult when running three protocols simultaneously.

Discard the solution immediately and do not administer. Visible particulates, cloudiness, or color change indicate protein aggregation or contamination. Both of which render the peptide inactive or potentially unsafe. Proper reconstitution technique requires injecting bacteriostatic water slowly down the vial wall rather than directly onto the lyophilized powder, then swirling gently (never shaking) to dissolve. Aggregation most commonly results from rapid reconstitution, repeated freeze-thaw cycles, or storage above 8°C. Always inspect reconstituted peptides under bright light before each administration and store in the original vial to minimize air exposure.

Examine dosing schedules and route of administration before concluding the peptide is inactive. Many neuroprotective peptides demonstrate dose-dependent effects with narrow therapeutic windows. VIP shows anti-inflammatory activity at 10–50 nmol/kg but loses selectivity at higher doses. Subcutaneous administration often requires 3–5× higher doses than intrathecal or intracerebroventricular routes due to systemic clearance. If your peptide shows no effect at published doses, verify reconstitution concentration, injection volume accuracy, and peptide purity via HPLC before escalating dose. Supraphysiological dosing sometimes reveals off-target effects that confound interpretation. IGF-1 LR3 above 200 μg/kg can activate insulin receptors and alter glucose metabolism independent of neuroprotection.